Telix Pharmaceuticals Limited
TLX
$10.68
-$0.06-0.54%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 0.00% | -110.86% | 0.00% | -116.26% | 0.00% |
| Total Depreciation and Amortization | 0.00% | 18.56% | 0.00% | 237.14% | 0.00% |
| Total Amortization of Deferred Charges | 0.00% | -- | -- | -- | -- |
| Total Other Non-Cash Items | 0.00% | -69.56% | 0.00% | -65.42% | 0.00% |
| Change in Net Operating Assets | 0.00% | -- | -- | -- | 0.00% |
| Cash from Operations | 0.00% | -297.43% | 0.00% | 326.86% | 0.00% |
| Capital Expenditure | 0.00% | -185.30% | 0.00% | -10.21% | 0.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 0.00% | 100.28% | 0.00% | -2,912.91% | 0.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 0.00% | 61.41% | 0.00% | 47.13% | 0.00% |
| Cash from Investing | 0.00% | 89.54% | 0.00% | -360.14% | 0.00% |
| Total Debt Issued | 0.00% | -- | -- | -- | 0.00% |
| Total Debt Repaid | 0.00% | 31.73% | 0.00% | -182.27% | 0.00% |
| Issuance of Common Stock | 0.00% | 67.46% | 0.00% | 179.34% | 0.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 0.00% |
| Cash from Financing | 0.00% | 72.77% | 0.00% | -100.70% | 0.00% |
| Foreign Exchange rate Adjustments | 0.00% | -121.32% | 0.00% | 589.93% | 0.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 0.00% | 71.96% | 0.00% | -164.50% | 0.00% |